CellaVision digitaliserar blodanalys och frigör viktig tid för sjukvården.
Redeye comments on Cellavision's first quarter 2025, which saw organic sales growth of 8%, with the highest growth in ASEA.
Redeye provides its first take on Cellavision’s Q2 report 2025, published this morning.
Redeye comments on Cellavision's first quarter 2025, which saw organic sales growth of 14%, an outstanding figure.
Redeye provides its first take on Cellavision’s Q1 report 2025, published this morning.
Redeye’s view on the Q4 report. The organic growth was weak, with large swings in the development in the different regions.
Redeye’s first take on the Q4 report this morning. Again, there were considerable changes in sales in the different regions during the quart...
Redeye’s view on the Q3 report. The organic growth was decent, with a gross margin that progressed.
Redeye’s first take on the Q3 report this morning. There were considerable changes in sales in the different regions during the quarter.
Redeye’s view on the Q2 report. The organic growth was decent, while the gross margin development comprised most of the deviation compared t...
Redeye’s first take on the Q2 report this morning. Despite some underlying differences, Cellavision presented a report aligned with our over...
Redeye’s view on the Q1 report. The organic growth was decent, while the gross margin development comprised most of the deviation compared t...
Redeye’s first take on the Q1 report this morning. Cellavision presented a slightly weaker top line, even though there is not a big differen...
Redeye’s view on the Q4 report. The organic growth was way above our and the market’s expectations.
Redeye’s first take on the Q4 report this morning. Cellavision presented a markedly stronger report straight through the accounts.
Redeye’s view on the Q3 report. The organic growth trend turned positive with improvement in APAC and continued positive development in the ...
Redeye’s first take on the Q3 report this morning. Cellavision presented a slightly stronger report on the top line, while the gross margin ...
Redeye’s view on the Q2 report. The organic growth trend continues to be weak, although the situation has improved during the quarter.
Redeye’s first take on the Q2 report this morning. Cellavision presented a report aligned with our lowered expectations but clearly performe...
Redeye’s view on the Q1 report. The trend continues to be weak as was indicated in the earlier profit warning.
Redeye’s comments on Cellavisions profit warning that was issued yesterday.
Redeyes view on the Q4 report. The report was weak, and the challenges continue to affect the company negatively.
Redeye’s first view on the Q4 report this morning. Cellavision clearly continues to see challenges evident in the weaker-than-expected repor...
Redeyes view on the Q3 report. The report was weak, in our opinion, even considering the challenges in the market and the typical seasonal f...
Redeyes view on the Q2 report. With a powerful report and above our estimates, we adjust our forecasts for the rest of the current year.
Redeyes view on the Q1 report. With a report slightly above our estimates, we only make minor adjustments to our forecasts for the current y...
Redeye views the Q2 from Cellavision this morning as very much in line with our expectations and continued solid recovery story.
